Legislators And Bond Holders Knocking At Valeant’s Door
This article was originally published in The Pink Sheet Daily
Executive Summary
The troubled drug maker received a notice of default from bondholders, while CEO Michael Pearson agreed to be deposed by the Senate’s Special Committee on Aging April 18.
You may also be interested in...
Valeant’s Pearson Is Out, As Hunt Begins For A CEO To Right The Wrongs
Valeant has begun the search for a new CEO, who will be charged with turning around the troubled company and likely divesting some assets. The company also calls out former CFO Howard Schiller for “improper conduct.”
At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath
Members of House Oversight Committee accuse Turing and Valeant of 'trashing' mainstream innovator companies with their drug pricing practices.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.